Pacer Advisors
ACOR

Pacer Advisors’s Acorda Therapeutics ACOR Stock Holding History

Pacer Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-46
Closed -$110K – 1104
2018
Q3 		$110K Buy
+46
New +$142K ﹤0.01% 1084
2018
Q1 		– Sell
-14
Closed -$36K – 1143
2017
Q4 		$36K Buy
+14
New +$39.8K ﹤0.01% 1051

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pacer Advisors's ACOR Position: Q4 2018 in Review

Pacer Advisors sold out of Acorda Therapeutics (ACOR) in Q4 2018, closing a stake of 46 shares — an estimated $110K sold.

Pacer Advisors first reported a position in ACOR in Q4 2017 and held it in 2 quarters. The position peaked at $110K in Q3 2018. 179 funds tracked by Wall St. Rank hold ACOR as of Q4 2018.

  • Pacer Advisors reported no remaining Acorda Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Pacer Advisors sold 46 Acorda Therapeutics shares in Q4 2018, an estimated $110K.
  • Pacer Advisors first reported a position in Acorda Therapeutics in Q4 2017 and held it in 2 quarters.
  • Pacer Advisors's Acorda Therapeutics position peaked at $110K in Q3 2018.
  • 179 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2018.

Based on Pacer Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.